EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real‐world, observational study

Tanvi Verma, Cody Marshall, Kossivi E Dantey, Diane V Thompson, Anna Banizs, Sydney D Finkelstein, Joseph DelTondo

Cancer Cytopathology · 2024

DOI: 10.1002/cncy.22829 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Cytopathology, 2024. Verfasst von Tanvi Verma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Thyroid Nodule, MicroRNAs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular analysis of fine‐needle aspiration biopsies (FNAB) improves the diagnostic accuracy of cytologically indeterminate thyroid nodules (ITNs). Recently, the use of MPTXv2 has been shown to further improve the accuracy of risk stratification of ITNs.

Methods

A total of 338 patient samples with atypia of undetermined significance ( n = 258) or follicular neoplasm ( n = 80) cytology diagnosis and corresponding surgical outcomes or clinical follow‐up, collected between 2016 and 2020 were included [Correction added on 19 June 2024, after first online publication: In the preceding sentence, the n values 260 and 78 have been changed to 258 and 80, respectively.]. All samples underwent multiplatform testing (MPTXv1), which includes an oncogene panel (ThyGeNEXT ® ) plus a microRNA risk classifier (ThyraMIR ® ). A blinded, secondary analysis was performed to assess the added utility of MPTXv2 (ThyraMIR ® v2). The average length of follow‐up for the surveillance group ( n = 248) was 30 months.

Results

Sensitivity at moderate threshold was 96% and specificity at positive threshold was 99% for MPTXv2. At 14% disease prevalence, the negative predictive value at the moderate threshold was 99% and the positive predictive value at the positive threshold was 89% for MPTXv2. MPTXv2 had fewer patients classified into the moderate‐risk group than MPTXv1, which was statistically significant ( p < .001). Using surgical resection, the gold standard for outcomes, MPTXv2 showed a statistically greater area under the curve ( p = .028) than MPTXv1, demonstrating greater accuracy for MPTXv2.

Conclusion

Both test versions demonstrated robust performance with low false‐positive molecular results. Data suggest that incorporation of MPTXv1, and more recently MPTXv2, into clinical practice within our healthcare network resulted in improved accuracy of ITN risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleMicroRNAsHumansFemaleMaleBiopsy, Fine-NeedleMiddle AgedAdultBiomarkers, TumorOncogenesThyroid NeoplasmsAgedAdenocarcinoma, Follicular

Stichwörter der Autor:innen

expression profilingmicroRNAmolecular testingthyroid nodule

Substanzen

MicroRNAsBiomarkers, Tumor

Autor:innen und Institutionen

  • Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Diane Vido Thompson, LLC, Murrysville, Pennsylvania, USA.
  • Interpace Diagnostics, Inc, Parsipanny, New Jersey, USA.

Zitieren

APA

Verma, T., Marshall, C., Dantey, K. E., Thompson, D. V., Banizs, A., Finkelstein, S. D., & DelTondo, J. (2024). The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real‐world, observational study. Cancer Cytopathology. https://doi.org/10.1002/cncy.22829

Vancouver

Verma T, Marshall C, Dantey KE, Thompson DV, Banizs A, Finkelstein SD, et al. The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real‐world, observational study. Cancer Cytopathology. 2024. doi:10.1002/cncy.22829

BibTeX
@article{Verma2024,
  author = {Verma, Tanvi and Marshall, Cody and Dantey, Kossivi E and Thompson, Diane V and Banizs, Anna and Finkelstein, Sydney D and DelTondo, Joseph},
  title = {The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real‐world, observational study},
  journal = {Cancer Cytopathology},
  year = {2024},
  doi = {10.1002/cncy.22829}
}
Kostenlos starten →